Neuroimmune modulation represents a promising treatment strategy that uses vagus nerve stimulation to reduce inflammation in ...

Celltrion, Inc. today announced that six abstracts will be presented at the 2025 Digestive Disease Week® (DDW) Annual Meeting, taking place May 3-6 in San Diego, California. The oral and poster ...

anti-CD40L antibody frexalimab which is in mid-stage testing for multiple sclerosis, and SAR441566, an orally-active TNF blocker that Sanofi thinks could be the biggest drug it has ever developed.

Added to its challenges, Biogen is also seeing greater competitive pressures on its multiple sclerosis therapies Tecfidera ... Johnson's Remicade (infliximab) – all TNF inhibitors for rheumatoid ...

Researchers at the University of Turku, Finland, have discovered a new biomarker that can predict the progression of multiple ...

Updates in relapsing-remitting MS from AAN 2025 examine neurofilament light protein level as a prognostic biomarker, safety and efficacy of ofatumumab, and benefit of early initiation of ozanimod.

Researchers at the University of Turku, Finland, have discovered a new biomarker that can predict the progression of multiple sclerosis (MS).

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

To provide the right treatment for multiple sclerosis (MS), it is important to know when the disease changes from ...

Functional neurological disorder can be hard to distinguish from other conditions. Some patients feel misunderstood and their ...

Selma Blair is "truly in remission" from multiple sclerosis. The 52-year-old actress was diagnosed with the autoimmune disease in 2018, but is now "feeling really well". Speaking to People ...

Selma Blair, who opened up about her diagnosis with multiple sclerosis in 2018, is “truly in remission,” she told People on Thursday, nearly seven years after she went public with her diagnosis.